NEW YORK — Binx Health said Monday that it has signed a US-wide distribution deal for its Binx io point-of-care test system for sexually transmitted diseases with healthcare services firm Cardinal Health.
Binx io is a US Food and Drug Administration-cleared platform for sexually transmitted infections, with a CLIA-waived test available for Chlamydia trachomatis and Neisseria gonorrhoeae. When Boston-based Binx launched the system — which uses a combination of PCR amplification and electrochemical detection — it centered its commercialization efforts on retail clinics and urgent care centers, striking distribution deals with McKesson and Fisher Healthcare, among others.
Late last year, Binx divested its digital health business in order to further focus on the point-of-care STD market.
"As we expand our commercial footprint, we're very excited about this collaboration with Cardinal Health," Binx CEO Jeffrey Luber said in a statement. "Serving 90 percent of US hospitals, 29,000 pharmacies, and 10,000 specialty physician office and clinics, their reach and brand are a leader in the industry."
Financial and other terms of the agreement with Cardinal were not disclosed.